VistaGen Therapeutics Inc. (NASDAQ: VTGN)’s stock price has decreased by -4.00 compared to its previous closing price of 0.15. Nevertheless, the company has seen a gain of 2.38% in its stock price over the last five trading days.
Is It Worth Investing in VistaGen Therapeutics Inc. (NASDAQ: VTGN) Right Now?
Moreover, the 36-month beta value for VTGN is 1.07. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
The average price recommended by analysts for VistaGen Therapeutics Inc. (VTGN) is $0.25, The public float for VTGN is 205.00M and currently, short sellers hold a 3.56% of that float. On March 17, 2023, VTGN’s average trading volume was 6.79M shares.
VTGN’s Market Performance
VTGN stock saw a decrease of 2.38% in the past week, with a monthly decline of -35.63% and a quarterly a decrease of 22.08%. The volatility ratio for the week is 12.60%, and the volatility levels for the last 30 days are 10.88% for VistaGen Therapeutics Inc. (VTGN). The simple moving average for the last 20 days is -13.43% for VTGN stock, with a simple moving average of -52.43% for the last 200 days.
VTGN Trading at -20.09% from the 50-Day Moving Average
After a stumble in the market that brought VTGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.82% of loss for the given period.
Volatility was left at 10.88%, however, over the last 30 days, the volatility rate increased by 12.60%, as shares sank -26.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.69% upper at present.
During the last 5 trading sessions, VTGN rose by +2.38%, which changed the moving average for the period of 200-days by -86.18% in comparison to the 20-day moving average, which settled at $0.1666. In addition, VistaGen Therapeutics Inc. saw 42.23% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VTGN starting from GIN JERRY B, who purchase 100,000 shares at the price of $0.18 back on Aug 18. After this action, GIN JERRY B now owns 100,000 shares of VistaGen Therapeutics Inc., valued at $17,870 using the latest closing price.
GIN JERRY B, the Director of VistaGen Therapeutics Inc., purchase 100,000 shares at $0.18 during a trade that took place back on Aug 18, which means that GIN JERRY B is holding 100,000 shares at $17,870 based on the most recent closing price.
Stock Fundamentals for VTGN
Current profitability levels for the company are sitting at:
- -4308.68 for the present operating margin
- +26.49 for the gross margin
The net margin for VistaGen Therapeutics Inc. stands at -4307.19. Equity return is now at value -158.20, with -125.10 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 12.29.
Conclusion
To wrap up, the performance of VistaGen Therapeutics Inc. (VTGN) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
